- Medicine Name: Welireg
- Generic Name: Belzutifan
- Dosage Form & Strength: Tablets: 40 mg
- Manufactured By: Merck
Welireg is a hypoxia-inducible factor inhibitor used to treat adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring prompt surgery.
Recommended Dosage: The recommended dosage is 120 mg administered orally (by mouth) once daily until the disease is progressive or unacceptable toxicity occurs. Welireg must be taken at the same time every day and may be taken with or without meal. Patients should swallow the Welireg tablets whole, without chewing, crushing, or splitting.
If a dose is missed/skipped, it can be taken as promptly as possible on the same day. Resume the regular daily dose schedule the very next day. Do not take additional tablets to make up for the missed/skipped dose.
In case vomiting occurs any time after taking the dosage, avoid retaking the dose. Patients should take the next scheduled dose on the very next day.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.